STENOVA - A Study to Evaluate Safety, Tolerability, PK and PD of AGMB-129 in Patients With Fibrostenotic Crohn's Disease

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

103

Participants

Timeline

Start Date

August 1, 2023

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2026

Conditions
Fibrostenotic Crohn's Disease
Interventions
DRUG

AGMB-129

Oral capsule

DRUG

Placebo

Matching oral capsule

Trial Locations (52)

1090

Medical University Of Vienna (AKH Wien), Vienna

2400

Bispebjerg Hospital, Copenhagen

2730

Herlev Hospital (University of Copenhagen), Herlev

5000

Odense University Hospital, Odense

5020

Gemeinnutzige Salzburger Landeskliniken Betriebsgesellschaft mbH (Landeskrankenhaus Salzburg/Regional Hospital Salzburg), Salzburg

8036

Medical University of Graz, Graz

14163

Servicegesellschaft Krankenhaus Waldfriede mbH Krankenhaus Waldfriede e.V Akademisches Lehrkrankenhaus der Charite, Berlin

20089

Humanitas Research Hospital IRCCS Istituto Clinico Humanitas, Milan

32825

Digestive and Liver Center of Florida, Orlando

33136

University of Miami, Miami

35010

Hospital Universitario de Gran Canaria, Las Palmas de Gran Canaria

38018

Gastro One, Cordova

40218

Gastroenterology Health Partners, Louisville

41013

Hospital Universitario Virgen del Rocio, Seville

41124

Azienda Ospedaliero Universitaria di Modena - Struttura Complessa di Gastroenterologia, Modena

44195

Cleveland Clinic, Cleveland

47150

Gastroenterology Health Partners, New Albany

48109

University of Michigan, Ann Arbor

52210

Planetmed Sp. z o.o., Wroclaw

55905

Mayo Clinic, Rochester

63110

Washington University School of Medicine, St Louis

71105

Louisiana Research Center, Shreveport

89081

Universitatsklinikum Ulm AöR (University of Ulm), Ulm

06518

Medical Research Center of Connecticut, LLC, Hamden

Unknown

Hospital Landstrasse, Department of Internal Medicine IV, Vienna

Nova Scotia Health Authority, Halifax

Ottawa Hospital Research Institute, Ottawa

Aarhus University Hospital, Department of Hepatology and Gastroenterology, Aarhus

Rigshospitalet - University Hospital Copenhagen, Copenhagen

"University Polyclinic Hospital G. Martino", Messina

Hospital San Raffaele, Milan

Sacred Heart Don Calabria, Negrar

"University Polyclinic Foundation Agostino Gemelli", Rome

Specialist Gastrology Centre GASTROMED, Bialystok

SOLUMED Medical Center, Poznan

Endoskopia Sp. z o.o., Sopot

H-T. Medical Center, Tychy

WSD Medi Clinical Sp. z o.o., Warsaw

VISTAMED, Wroclaw

AB T2N 4Z6

University of Calgary, Calgary

T5R1W2

Gastroenterology and Internal Medicine Research Institute (GIRI), Edmonton

T6K 4B2

South Edmonton Gastroenterology Research Clinic, Edmonton

ON M6A 3B4

TIDHI Innovation Inc., North York

BC V6Z 2K5

(G.I.R.I) GI Research Institute, Vancouver

12203/12200

Charite Universitatsmedizin Berlin KöR Campus Benjamin Franklin Medizinische, Berlin

06108

BSF Studiengesellschaft UG (Unternehmergesellschaft, haftungsbeschränkt), Halle

00152

Azienda Ospedaliera San Camillo Forlanini, Rome

40-748

Vita Longa Sp. z.o.o., Katowice

20-582

MEDRISE Sp. z o.o., Lublin

00-728

WIP Warsaw IBD Point, Warsaw

22-400

ETG Zamość, Zamość

08036

Hospital Clinic de Barcelona, Barcelona

All Listed Sponsors
lead

Agomab Spain S.L.

INDUSTRY

NCT05843578 - STENOVA - A Study to Evaluate Safety, Tolerability, PK and PD of AGMB-129 in Patients With Fibrostenotic Crohn's Disease | Biotech Hunter | Biotech Hunter